Lipid analogs for treating viral infections
AssigneeWake Forest University
InventorsLouis S. Kucera, Susan L. Morris-Natschke, Khalid S. Ishaq
Life of this patent
Estimating the term…
Abstract
A method of treating viral infections, and in particular HIV-1, hepatitis B virus and herpes viruses, is disclosed. The method comprising administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.
Claims33
A method of combating a viral infection in a subject in need of such treatment comprising administering to said subject an effective infection-combating amount of a compound of Formula I ##STR11## wherein:
- R.sub.1 is a branched or unbranched, saturated or unsaturated C.sub.8 to C.sub.12 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- X is selected from the group consisting of NHCO, CH.sub.3 NCO, CONH, CONCH.sub.3, NH, and NCH.sub.3 ;
- R.sub.2 is a branched or unbranched, saturated or unsaturated C.sub.6 to C.sub.14 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo or amine;
- Y is selected from the group consisting of NHCO, CH.sub.3 NCO, CONCH.sub.3, S, SO, SO.sub.2, O, NH, and NCH.sub.3 ;
- R.sub.6 is a branched or unbranched C.sub.2 to C.sub.6 alkyl group;
- and
- R.sub.3, R.sub.4, and R.sub.5 are independently methyl or ethyl, or R.sub.3 and R.sub.4 together with N form a heterocyclic ring having five or six members and R.sub.5 is methyl or ethyl;
- or a pharmaceutical salt thereof.
A method of inhibiting replication of a hepatitis B virus in a subject in need of such treatment comprising administering to said subject a viral replication-inhibiting amount of a compound of Formula I ##STR12## wherein:
- R.sub.1 is a branched or unbranched, saturated or unsaturated C.sub.8 to C.sub.12 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo or amine;
- X is selected from the group consisting of NHCO, CH.sub.3 NCO, CONH, CONCH.sub.3, NH, and NCH.sub.3 ;
- R.sub.2 is a branched or unbranched, saturated or unsaturated C.sub.6 to C.sub.14 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo ox amine;
- Y is selected from the group consisting of NHCO, CH.sub.3 NCO, CONH, CONCH.sub.3, S, SO, SO.sub.2, O, NH, and NCH.sub.3 ;
- R.sub.6 is a branched or unbranched C.sub.2 to C.sub.6 alkyl group;
- and
- R.sub.3, R.sub.4, and R.sub.5 are independently methyl or ethyl, or R.sub.3 and R.sub.4 together with N form a heterocyclic ring having five or six members and R.sub.5 is methyl or ethyl;
- or a pharmaceutical salt thereof.
A method of inhibiting the incorporation of HIV-1 major glycoprotein gp120 into a cell membrane in a subject infected with HIV-1, comprising administering to said subject a compound of Formula I in an amount effective to inhibit such incorporation:
- ##STR13## wherein:
- R.sub.1 is a branched or unbranched, saturated or unsaturated C.sub.8 to C.sub.12 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- X is selected from the group consisting of NHCO, CH.sub.3 NCO, CONH, CONCH.sub.3, NH, and NCH.sub.3 ;
- R.sub.2 is a branched or unbranched, saturated or unsaturated C.sub.6 to C.sub.14 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- Y is selected from the group consisting of NHCO, CH.sub.3 NCO, CONCH.sub.3, S, SO, SO.sub.2, O, NH, and NCH.sub.3 ;
- R.sub.6 is a branched or unbranched C.sub.2 to C.sub.6 alkyl group;
- and
- R.sub.3, R.sub.4, and R.sub.5 are independently methyl or ethyl, or R.sub.3 and R.sub.4 together with N form a heterocyclic ring having five or six members and R.sub.5 is methyl or ethyl;
- or a pharmaceutical salt thereof.
A compound of Formula I ##STR14## wherein:
- R.sub.1 is a branched or unbranched, saturated or unsaturated C.sub.8 to C.sub.12 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- X is selected from the group consisting of CH.sub.3 NCO, CONH, and CONCH.sub.3 ;
- R.sub.2 is a branched or unbranched, saturated or unsaturated C.sub.6 to C.sub.14 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- Y is selected from the group consisting of NHCO, CH.sub.3 NCO, CONCH.sub.3, S, SO, SO.sub.2, and O;
- R.sub.6 is a branched or unbranched C.sub.2 to C.sub.6 alkyl group;
- and
- R.sub.3, R.sub.4, and R.sub.5 are independently methyl or ethyl, or R.sub.3 and R.sub.4 together with N form a heterocyclic ring having five or six members and R5 is methyl or ethyl.
A method of combating tumors in a subject in need of such treatment comprising administering to said subject an effective amount of a compound of Formula I ##STR15## wherein:
- R.sub.1 is a branched or unbranched, saturated or unsaturated C.sub.6 to C.sub.18 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- X is selected from the group consisting of CH.sub.3 NCO, CONH, CONCH.sub.3, S, SO, S.sub.2, and O;
- R.sub.2 is a branched or unbranched, saturated or unsaturated C.sub.6 to C.sub.14 alkyl group optionally substituted from 1 to 5 times with --OH, --COOH, oxo, or amine;
- Y is selected from the group consisting of NHCO, CH.sub.3 NCO, CONH, CONCH.sub.3, S, SO, SO.sub.2, and O;
- R.sub.6 is a branched or unbranched C.sub.2 to C.sub.6 alkyl group;
- and
- R.sub.3, R.sub.4, and R.sub.5 are independently methyl or ethyl, or R.sub.3 and R.sub.4 together with N form a heterocyclic ring having five or six members and R.sub.5 is methyl or ethyl;
- or a pharmaceutical salt thereof.
Dependencies are inferred from the claim text.